This article will address the topic of Flubromazepam, which has currently generated great interest due to its multiple implications in different areas. Flubromazepam has been the subject of study and research by experts in various disciplines, who have sought to thoroughly understand its characteristics, its impact and its relevance in society. From its origins to its evolution today, Flubromazepam has sparked debates and reflections around its influence on culture, economy, politics, technology, the environment and other fundamental aspects of human life. This article aims to present a comprehensive and updated view of Flubromazepam, exploring its many facets and its importance in the contemporary world.
Flubromazepam is a benzodiazepine derivative which was first synthesized in 1960, but was never marketed and did not receive any further attention or study until late 2012 when it appeared on the grey market as a novel designer drug.
An alternate isomer, 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-2H-1,4-benzodiazepin-2-one or "iso-flubromazepam", may have been sold under the same name.
Legal status
United Kingdom
In the UK, flubromazepam has been classified as a Class C drug by the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.
United States
Flubromazepam, clonazolam, and flubromazolam are Schedule I controlled substances under Virginia State Law.
^US 3136815, "Amino substituted benzophenone oximes and derivatives thereof"
^ abMoosmann B, Huppertz LM, Hutter M, Buchwald A, Ferlaino S, Auwärter V (November 2013). "Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics". Journal of Mass Spectrometry. 48 (11): 1150–9. Bibcode:2013JMSp...48.1150M. doi:10.1002/jms.3279. PMID24259203.
^"Flubromazepam". New Synthetic Drugs Database. 12 November 2023.
^Pettersson Bergstrand M, Helander A, Hansson T, Beck O (April 2017). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis. 9 (4): 640–645. doi:10.1002/dta.2003. PMID27366870.
^Høiseth G, Tuv SS, Karinen R (November 2016). "Blood concentrations of new designer benzodiazepines in forensic cases". Forensic Science International. 268: 35–38. doi:10.1016/j.forsciint.2016.09.006. PMID27685473.